Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

Phase 2 Unknown 275 enrolled Angion Biomedica Corp CTI Clinical Trial and Consulting Services · collab Clinical Accelerator · collab Everest Clinical Research · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The objective of the study is to assess the safety and efficacy of ANG-3777 in preventing AKI compared to placebo when administered to patients at risk for developing acute kidney injury (AKI) following cardiac surgical procedures involving cardiopulmonary bypass (CPB).

Timeline

Start: 2017-02-24
Primary completion: 2021-08
Completion: 2021-08

Publications

Ayad SS, Beaver T, Corteville D, Swaminathan M, Pearl RG, Aslam S, Csomor PA, Alperovich G, Neylan J. Development of and recovery from acute kidney injury after cardiac surgery: Randomized phase 2 trial of the hepatocyte growth factor mimetic ANG-3777. J Thorac Cardiovasc Surg. 2025 Oct;170(4):1125-1132.e2. doi: 10.1016/j.jtcvs.2024.11.024. Epub 2024 Nov 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	TEREVALEFIM	Small molecule	2 mg/kg	Intravenous

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

Summary

Timeline

Publications

Drugs

Indications